Reading the tape
NASDAQ: FEMY
Femasys Inc.
Healthcare · Medical - Instruments & Supplies
Market Cap
$11.57M
52w High
$1.22
52w Low
$0.31
P/E
-0.83
Volume
151.90K
Outstanding Shares
29.45M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -68.48%Revenue (TTM): 40.77%FCF (TTM): 5.3%P/S: 11th pct
What changed
The stock fell 68.48% over the last year. Revenue grew 40.77% over the trailing twelve months. Operating margin moved from -1,091.75% to -766.95%. Free cash flow grew 5.3% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -766.95%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States.
CEOKathy Lee-Sepsick
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees69
IPO dateJun 18, 2021
Valuation
Forward P/E—
EV/EBITDA-1.15
Enterprise value$18.22M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth39.86%
Gross margin61.96%▼6.90%vs FY2024
Operating margin-766.95%▲29.75%vs FY2024
ROE-317.38%▲61.13%vs FY2024
Analyst consensus
RatingBuy
Target price—
5
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.07 · Revenue est $767K
View